AXL and B-cell chronic lymphocytic leukemia: We found that TP-0903 was effective at inducing apoptosis of CLL B-cells from (Figure 2B) the ibrutinib exposed CLL patients where CLL B-cell Axl expression levels varied from 2.7-91.3%.